BIOLASE Inc. (NASDAQ:BIOL) does about 9.00M shares in volume on a normal day but saw 3237718 shares change hands in Tuesday trading. The company now has a market cap of 27.44M USD. Its current market price is $0.30, marking a decrease of -4.86% compared to the previous close of $0.31. The 52 week high reached by this stock is $1.16 whilst the lowest price level in 52 weeks is $0.21. The script in recent trading has seen the stock touch a high of $0.3149 and a low of $0.2841.
BIOLASE Inc. (BIOL) has a 20-day trading average at $0.3797 and the current price is -74.44% off the 52-week high compared with 40.19% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.4225 and its 200-day simple moving average is $0.5083. If we look at the stock’s price movements over the week, volatility stands at 6.82%, which decreases to 6.29% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 27.94 to suggest the stock is oversold.
3 analysts observing the BIOLASE Inc. (BIOL) stock have set the 12-month price targets for the company’s shares at between $1.15 and $2.00. The median price target is 82.86% away from the current levels at $1.75.
FactSet Research has provided data showing that 3 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 3 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on June 19, 2019 when The Benchmark Company initiated the stock to “Speculative Buy” and issued a price target of $2. WallachBeth downgraded its price target at $4-$2.50.
The current price level is -23.28%, -30.75%, and -41.93% away from its SMA20, SMA50, and SMA200 respectively, with the BIOL price moving above the 50-day SMA on September 01. BIOLASE Inc. (BIOL) stock is down -11.36% over the week and -29.74% over the past month. Its price is -46.48% year-to-date and -72.09% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$0.12 above consensus estimates by $0.05. The company’s next earnings report is expected on 11/04/2020, with forecasts estimating quarterly EPS at -$0.06 and -$0.3 for whole year. BIOL’s earnings per share are forecast to grow by 31.80% this year and 70.00% over next year. Expected sales for next quarter are $10.59 million, which analysts say will come at $23.89 million for the current fiscal year and next year at $41.5 million. In addition, estimates put the company’s current quarterly revenue at an average of $5.56 million.
Its 12-month price target is $1.75. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $1.15, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $2.00.
Outstanding shares total 92.19M with insiders holding 27.02% of the shares and institutional holders owning 37.78% of the company’s common stock. The company has a return on investment of -112.90%. The beta has a value of 1.97. Price to book ratio is 9.86 and price to sales ratio is 1.04.
According to a U.S. Securities and Exchange Commission filing, Vanguard Total Stock Market Index has reduced its position in BIOLASE Inc. (BIOL) to 815,191 shares, mirroring a recent drop by 0.00%. Vanguard Total Stock Market Index dumped 0.0 shares of BIOLASE Inc. common stock bringing its total worth to about $0.33 million at the end of recent close, SEC documents show. Vanguard Total Stock Market Index isn’t the only investment manager who changed stakes and is followed by Vanguard Extended Market Index Fu, which sold off 0.0 shares to end up with 184,507 shares worth $75463.0. Fidelity Extended Market Index Fu cut their holdings by 0.00% in the company over the course of the most recent quarter. It now holds a 0.07% position in BIOLASE Inc. thanks to 34145.0 shares amounting to $13965.0.